These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 24839275)
21. The Impact on Resource Utilization of Supportive Care Consults on Patients at the University of North Carolina Hospital, 2010-2012. Westfall K; Moore D; Meeneghan M; Jarr S; Valgus J; Bernard S J Palliat Med; 2018 Feb; 21(2):216-219. PubMed ID: 28813627 [TBL] [Abstract][Full Text] [Related]
22. Incidence, admission rates, and economic burden of pediatric emergency department visits for urinary tract infection: data from the nationwide emergency department sample, 2006 to 2011. Sood A; Penna FJ; Eleswarapu S; Pucheril D; Weaver J; Abd-El-Barr AE; Wagner JC; Lakshmanan Y; Menon M; Trinh QD; Sammon JD; Elder JS J Pediatr Urol; 2015 Oct; 11(5):246.e1-8. PubMed ID: 26005017 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH Value Health; 2009; 12(2):217-25. PubMed ID: 18673353 [TBL] [Abstract][Full Text] [Related]
24. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia. Ghalaut PS; Sen R; Dixit G J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972 [TBL] [Abstract][Full Text] [Related]
25. Impact of neutropenia on delivering planned chemotherapy for solid tumours. Khan S; Dhadda A; Fyfe D; Sundar S Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887 [TBL] [Abstract][Full Text] [Related]
26. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224 [TBL] [Abstract][Full Text] [Related]
27. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Blais L; Forget A; Ramachandran S Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680 [TBL] [Abstract][Full Text] [Related]
28. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia. Pérez Velasco R J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168 [TBL] [Abstract][Full Text] [Related]
29. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Johnston EM; Crawford J Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594 [TBL] [Abstract][Full Text] [Related]
30. Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase. Iqbal MP; Burney IA Pak J Pharm Sci; 2014 Mar; 27(2):245-8. PubMed ID: 24577909 [TBL] [Abstract][Full Text] [Related]
31. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities. Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302 [TBL] [Abstract][Full Text] [Related]
32. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328 [TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522 [TBL] [Abstract][Full Text] [Related]
34. Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. Jolis L; Carabantes F; Pernas S; Cantos B; López A; Torres P; Funes C; Caballero D; Benedit P; Salar A; Eur J Cancer Care (Engl); 2013 Jul; 22(4):513-21. PubMed ID: 23730920 [TBL] [Abstract][Full Text] [Related]
35. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting. Tuffaha HW; Treish IM; Zaru L J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866 [TBL] [Abstract][Full Text] [Related]
36. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755 [TBL] [Abstract][Full Text] [Related]
37. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Repetto L; Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660 [TBL] [Abstract][Full Text] [Related]
38. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia. Rofail P; Tadros M; Ywakim R; Tadrous M; Krug A; Cosler LE Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):699-709. PubMed ID: 23252353 [TBL] [Abstract][Full Text] [Related]
39. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Riikonen P; Rahiala J; Salonvaara M; Perkkiö M Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114 [TBL] [Abstract][Full Text] [Related]
40. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Brooks TW; Creekmore FM; Young DC; Asche CV; Oberg B; Samuelson WM Pharmacotherapy; 2007 May; 27(5):684-90. PubMed ID: 17461703 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]